7.342: Week 5 Questions
Post discussion, questions, or comments about the Week 5 course material here.
Amber
Elizabeth
Nielsen et al.
I agree with Manpreet in not understand the presence of HA in the HA immunoprecipitation. I in theory understand what they are trying to prove in “This methylase binds the pocket domain of Rb because tumour-derived mutations in the pocket (F706C), or truncations of the pocket (delta928 and delta737), abolish binding to the methylase,” (p563 top left) but I do not understand how figure 1d explains this.
Ayyanathan et al.
Georgi
Holly
Nielson et al: This paper shows that SUV39H1 and HP1 are both involved in the gene silencing mechanism of the tumour suppressor Rb. What is the functional significance/ therapeutic potential of this knowledge? Have mutations in either HP1 or SUV39H1 themselves been implicated in cancer? Also, the 2nd paper makes reference to the dose dependent nature of HP1 repression. Column 4 in fig 2d (of Nielson paper) shows that SUV39H1 mediates some repression even without Rb being present – would increasing levels of HP1 compensate for Rb loss of function?
Ayyanathan et al: Why is the KRAB-PAX3-HBD protein not required to maintain the silent state? I.e. why are the other components of the repression pathway able to remain bound when they presumably couldn’t initially bind without KRAB-PAX3-HBD? Also, how (and is) the repression reversed? (Presumably the HP1 etc must dissociate, what causes this?)
Kathy
Manpreet
Nielsen et al: In figure 1c, the control immunoprecipation (i.e. using the HA) shows some H3 methylase activity. I'm sure the activity shown isn't statisically significant, but I can't think of any reason for the control to show any activity.
Ayyanathan et al: The paper mentions two different homologs of HP1 - Alpha and Gamma. They also mention that HP1 Alpha is inducibly bound; and that HP1 gamma is constituitively bound. This is briefly mentioned again in the conclusion - have studies been done showing specific functioanl differences between the isoforms?
Zak
.
